ATE79030T1 - Arzneimittel mit guter stabilitaet. - Google Patents

Arzneimittel mit guter stabilitaet.

Info

Publication number
ATE79030T1
ATE79030T1 AT89105625T AT89105625T ATE79030T1 AT E79030 T1 ATE79030 T1 AT E79030T1 AT 89105625 T AT89105625 T AT 89105625T AT 89105625 T AT89105625 T AT 89105625T AT E79030 T1 ATE79030 T1 AT E79030T1
Authority
AT
Austria
Prior art keywords
drug
good stability
microcrystalline cellulose
binder
pravastatin
Prior art date
Application number
AT89105625T
Other languages
English (en)
Inventor
Yatindra Mohan Joshi
Pierina Chiesa
Nemichand Bherulal Jain
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22643088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE79030(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Application granted granted Critical
Publication of ATE79030T1 publication Critical patent/ATE79030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vending Machines For Individual Products (AREA)
  • Formation And Processing Of Food Products (AREA)
AT89105625T 1988-03-31 1989-03-30 Arzneimittel mit guter stabilitaet. ATE79030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/176,127 US5030447A (en) 1988-03-31 1988-03-31 Pharmaceutical compositions having good stability
EP89105625A EP0336298B1 (de) 1988-03-31 1989-03-30 Arzneimittel mit guter Stabilität

Publications (1)

Publication Number Publication Date
ATE79030T1 true ATE79030T1 (de) 1992-08-15

Family

ID=22643088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89105625T ATE79030T1 (de) 1988-03-31 1989-03-30 Arzneimittel mit guter stabilitaet.

Country Status (14)

Country Link
US (1) US5030447A (de)
EP (1) EP0336298B1 (de)
CN (1) CN1026861C (de)
AT (1) ATE79030T1 (de)
AU (1) AU624117B2 (de)
CA (1) CA1323836C (de)
CY (1) CY1675A (de)
DE (1) DE68902344T2 (de)
DK (1) DK173862B1 (de)
HK (1) HK40093A (de)
IE (1) IE62956B1 (de)
NZ (1) NZ228076A (de)
SG (1) SG107292G (de)
ZA (1) ZA891424B (de)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
GR1002098B (en) * 1989-06-08 1995-12-28 Squibb & Sons Inc Pharmaceutical composition having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
HU221849B1 (hu) * 1991-12-12 2003-02-28 Novartis Ag. HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények
DE69324504T2 (de) * 1993-01-19 1999-08-26 Warner Lambert Co Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
EP0812195B1 (de) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
PT814782E (pt) * 1995-12-22 2003-04-30 Nissan Chemical Ind Ltd Composicao farmaceutica estabilizada com um agente basico
EP0839526A3 (de) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Festes pharmazeutisches Präparat mit schneller Auflösungs- oder Disintegrationeigenschaften
DE19724123A1 (de) 1997-06-09 1998-12-10 Voith Sulzer Papiermasch Gmbh Vorrichtung und Verfahren zum Überführen eines Einfädelstreifens oder einer Materialbahn
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
CA2323849C (en) * 1997-12-22 2002-06-11 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
KR100281521B1 (ko) * 1998-03-31 2001-02-15 김종인 프라바스타틴나트륨이 함유된 약제 조성물
ES2559766T3 (es) 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
US6232351B1 (en) * 1998-05-22 2001-05-15 Amway Corporation Co-processed botanical plant composition
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AR019935A1 (es) 1998-07-28 2002-03-27 Takeda Pharmaceutical Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6391583B1 (en) 1998-12-18 2002-05-21 Wisconsin Alumni Research Foundation Method of producing antihypercholesterolemic agents
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
MXPA01009839A (es) * 1999-03-31 2002-06-21 Abbott Lab Nuevas formulaciones que comprenden agentes reguladores de lipido.
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
DK2382970T3 (da) * 2000-04-10 2013-03-25 Teva Pharma Stabile farmaceutiske sammensætninger, der indeholder 7-substitueret-3,5-dihydroxyheptansyrer eller 7-substitueret-3,5-dihydroxyheptensyrer
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SI1292293T1 (en) 2000-06-09 2004-06-30 LEK farmacevtska dru�ba d.d. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
ATE418979T2 (de) 2000-06-09 2009-01-15 Lek Pharmaceuticals Stabilisiertes arzneimittel und arzneizubereitung
US20020183383A1 (en) * 2001-02-27 2002-12-05 Rene Belder Pharmaceutical compositions
KR20030096294A (ko) * 2001-03-27 2003-12-24 랜박시 래보러터리스 리미티드 프라바스타틴의 안정한 약학적 조성물
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
JP2005500307A (ja) * 2001-06-21 2005-01-06 アンドルックス ファーマスーティカルズ インコーポレーテッド プラバスタチンを含む安定な徐放性薬剤組成物
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US6967218B2 (en) 2002-01-11 2005-11-22 Biovail Laboratories, Inc. Pravastatin pharmaceutical formulations and methods of their use
EP1905431A1 (de) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung
EA200401227A1 (ru) * 2002-03-22 2005-04-28 Рэнбакси Лабораториз Лимитед Система доставки лекарства с контролируемым высвобождением, включающая правастатин
CA2480325A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
US20040132806A1 (en) * 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
RU2315603C2 (ru) 2002-12-20 2008-01-27 Ф.Хоффманн-Ля Рош Аг Композиция с высокой дозой ибандроната
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP2289507A1 (de) * 2003-03-17 2011-03-02 Japan Tobacco, Inc. Pharmazeutische CETP-Inhibitor-Zubereitungen
MXPA05009976A (es) * 2003-03-17 2005-11-04 Japan Tobacco Inc Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo].
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
WO2006008757A2 (en) * 2004-05-05 2006-01-26 Cadila Healthcare Limited Stabilized pharmaceutical compositions of pravastatin
EP1786414A4 (de) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc Neue pharmazeutische statin-zusammensetzungen und relevante behandlungsverfahren
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
CA2573316A1 (en) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel fenofibrate formulations and related methods of treatment
CN100453116C (zh) * 2004-10-19 2009-01-21 上海中西制药有限公司 复方氨茶碱片剂及其制备方法
AU2005305460B2 (en) * 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US7511152B2 (en) 2004-12-09 2009-03-31 Merck & Co., Inc. Estrogen receptor modulators
US8722734B2 (en) 2005-03-02 2014-05-13 Merck Sharp & Dohme Corp. Composition for inhibition of cathepsin K
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2083831B1 (de) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Verfahren zur behandlung von fettsäure-synthese-hemmern
EP1911441A3 (de) * 2006-10-11 2008-08-06 Lupin Limited Farbstabile pharmazeutische Dosierungsformen mit kontrollierter Freigabe von HMG-COA-Reduktase-Hemmern, die frei von Alkalisierungs- oder Pufferagenzien sind
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2394643B1 (de) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Topiramat-Formulierungen mit verzögerter Freisetzung
EP2336120B1 (de) 2007-01-10 2014-07-16 MSD Italia S.r.l. Kombinationspräparate enthaltend amidsubstituierte Indazole als Poly-(ADP-ribose)-Polymerase (PARP)-Hemmer
JP5330274B2 (ja) 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
CN101795684A (zh) * 2007-04-09 2010-08-04 赛多斯有限责任公司 他汀类化合物与抗肥胖药的组合
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
CN101732267B (zh) * 2008-11-14 2012-05-30 丽珠医药集团股份有限公司 普伐他汀钠片剂、其用途及其制备方法
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2803558C (en) * 2010-06-30 2018-05-29 Mochida Pharmaceutical Co., Ltd. .omega.3 fatty acid compound preparation
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
EP4079856A1 (de) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (de) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Kondensierte pyrazolderivate als neue erk-hemmer
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP2698159A4 (de) * 2011-04-12 2014-11-05 Sawai Seiyaku Kk Pitavastatinhaltiges präparat und herstellungsverfahren dafür
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
TWI636783B (zh) * 2012-04-18 2018-10-01 友霖生技醫藥股份有限公司 含匹伐他汀（ｐｉｔａｖａｓｔａｔｉｎ）穩定配方的醫藥組合物
EP2844261B1 (de) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. Sina-zusammensetzungen
EP2900241B1 (de) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Neuartige verbindungen als erk-hemmer
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
IN2013MU02470A (de) * 2013-07-25 2015-06-26 Cadila Healthcare Ltd
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
JP6454335B2 (ja) 2013-10-08 2019-01-16 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． カテプシンシステインプロテアーゼ阻害剤
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP3094323A4 (de) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668A4 (de) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. Prmt5-inhibitoren
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865935A (en) * 1972-08-10 1975-02-11 Abbott Lab Tableting of erythromycin base
US3891755A (en) * 1973-07-11 1975-06-24 Abbott Lab Dosage formulation for erythromycin cetyl sulfate
US4342767A (en) * 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4681759A (en) * 1985-05-08 1987-07-21 Ortho Pharmaceutical Corporation Rioprostil-PVP complex
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments

Also Published As

Publication number Publication date
DK155689A (da) 1989-10-01
ZA891424B (en) 1989-10-25
AU3027689A (en) 1989-10-05
DK173862B1 (da) 2002-01-07
CA1323836C (en) 1993-11-02
IE62956B1 (en) 1995-03-08
NZ228076A (en) 1991-04-26
US5030447A (en) 1991-07-09
HK40093A (en) 1993-04-30
DE68902344T2 (de) 1993-01-07
EP0336298A1 (de) 1989-10-11
IE890929L (en) 1989-09-30
DE68902344D1 (de) 1992-09-10
SG107292G (en) 1992-12-24
AU624117B2 (en) 1992-06-04
EP0336298B1 (de) 1992-08-05
JP2935220B2 (ja) 1999-08-16
JPH026406A (ja) 1990-01-10
CN1026861C (zh) 1994-12-07
CY1675A (en) 1993-10-10
DK155689D0 (da) 1989-03-30
CN1036508A (zh) 1989-10-25

Similar Documents

Publication Publication Date Title
ATE79030T1 (de) Arzneimittel mit guter stabilitaet.
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
DK0698389T3 (da) Matrix med reguleret frigivelse til farmaceutiske præparater
BR9810984A (pt) Composto de triazol, uso do mesmo, e, composição farmacêutica
AR064896A2 (es) Composicion farmaceutica no higroscopica
DE69028109D1 (de) Medizinische beatmungsgeräte
ATE66143T1 (de) Feste zubereitung mit langsamer freisetzung.
DE3772924D1 (de) Gegen oxydierung und verfaerbung stabilisierte arzneimittelzubereitungen.
SE8804629D0 (sv) New therapeutically active compounds
DK0724885T3 (da) Pernasal sammensætning og pernasalt præparat indeholdende dette
DE58906867D1 (de) Wässrige Dispersion von 2-(2'-Hydroxyphenyl-)benzotriazolen.
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
IT1228211B (it) Agglomerato combustibile resistente all'acqua, procedimento per la sua preparazione e composizione di materiali usata in tale procedimento.
PH27257A (en) Therapeutically active chloro substituted benzimidazole
AU2437388A (en) 2, 3-Dihydro-2, 2-dimethyl-3-hydroxy-6-(trifluoroalkoxy)-4- amino derivatives
AU7797787A (en) The use of 2',3'-dideoxycytidin-2'-ene(2',3'-dideoxy-2',3'- didehydrocytidine) in treating patients infected with retroviruses
DE3871791D1 (de) Verwendung von homo- und copolymeren des vinylalkohols zum tablettieren von wirkstoffen.
CO5031291A1 (es) Composicion farmaceutica
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
DE3867042D1 (de) Pharmazeutische praeparate.
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
GR890100379A (el) Φαρμακευτικές συνθέσεις έχοντας καλή σταθερότητα.
DK623984D0 (da) Farmaceutisk doseringsenhed
KR880002520A (ko) 망막증의 치료방법
KR900012622A (ko) 피부질환치료 조성물

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time